Phase 2 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Alzheimer's disease, confirmed by biological markers, meeting the most recent (2024) diagnostic guidelines.
- You have been assessed as having agitation that meets a specific internationally recognised definition used by specialists in older adult mental health.
- You have had symptoms of agitation for at least four weeks before the initial screening appointment.
- You scored 24 or below on a standard memory and thinking test called the MMSE-1.
- You scored 4 or above on the agitation/aggression section of a specific behaviour rating scale used in care settings (NPI-NH).
- You have been living in the same place (such as a nursing home, assisted living facility, or your own home) for at least six weeks before screening — and if living at home, you have a caregiver or family member who can be involved in the study.
- You are able to move around on your own, even if you use a wheelchair, walking frame, or other mobility aid.
Who may not be able to join:
- You are currently experiencing severe delusions or hallucinations that require a hospital stay.
- You have a history of bipolar disorder, schizophrenia, or schizoaffective disorder.
- You have had a major depressive episode that included psychotic features (such as hallucinations or delusions) within the past 12 months.
- You have experienced a state of sudden confusion (delirium) within the last 30 days before screening.
- There may be additional criteria not listed here that could affect eligibility (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Cohen-Mansfield Agitation Inventory (CMAI) total score from baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.